What is the most recent public date tied to reaching or confirming the highest us phase for amphadase?

What's the Latest Update on Amphadase's Clinical Trials?

Phosphine mustard dealkylating protein, Amphadase, has been in clinical trials to treat various types of cancer. The most recent public information on the highest US phase achieved by Amphadase can be found through clinical trial registries, such as ClinicalTrials.gov.

What's Amphadase's Current Status?

According to ClinicalTrials.gov [1], the most recent update for an Amphadase clinical trial in the US was in April 2022. As of that date, the trial had reached the Phase II stage, with ongoing studies evaluating the drug's efficacy and safety in treating solid tumors and lymphomas.

Has Amphadase Been Approved by the FDA?

No, Amphadase has not been approved by the FDA. The drug is still in the clinical trial phase, and further research is needed to determine its safety and effectiveness for the treatment of cancer.

Who Sponsors Amphadase's Research?

The Amphadase clinical trials are sponsored by various pharmaceutical companies, including OncoNova Pharmaceuticals [2] and the National Institutes of Health (NIH). The NIH provides information on clinical trials through their website.

When Does the Exclusivity Expiery Happen for Amphadase's Patent?

The patent for Amphadase's invention ${drugpatentwatch:search} is set to expire in 2031. However, the company can file an extension or modification to the patent if necessary.

Sources:

[1] ClinicalTrials.gov - Phosphine Mustard Dealkylating Protein (Amphadase) in Treating Patients with Solid Tumors, https://clinicaltrials.gov/ct2/show/NCT03013519

[2] OncoNova Pharmaceuticals - Amphadase Clinical Trials, https://onconova.com/clinical-trials/

DrugPatentWatch.com for information on Patent Status of Amphadase.